Treatment Information

Back

Prostate Cancer treatment details. Biologic therapy.

University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States.

Survival: monthsCountry:United States
Toxiciy Grade:3City/State/Province:Madison, Wisconsin
Treatments:Biologic therapyHospital:University of Wisconsin Comprehensive Cancer Center
Drugs:Journal:Link
Date:Sep 2002

Description:

Patients: This Phase I trial involved 25 patients with hormone refractory prostate cancer. The median age was 72 years. All patients had undergone prior hormonal treatment and 10 patients had undergone prior radiation therapy. Metastatic sites included bone and soft tissue.

Treatment: The treatment consisted of 1 alpha-hydroxyvitamin D2 (a vitamin D analogue).

Toxicity: At the highest dosage one patient developed a reversible grade 3 increase in serum creatinine.

Results: Two patients had an objective response but eventually their cancers progressed. Overall survival was not discussed.

Support: Support for the study was provided by Bone Care International. This company is involved in the development and marketing of 1 alpha-hydroxyvitamin D2.

Correspondence: George Wilding, MD





Back